Answers are grounded in this paper and cite their sources.
Idiopathic pulmonary fibrosis (IPF) is a chronic debilitating lung disease, characterised by progressive deposition of excessive extracellular matrix in the lung parenchyma [1]. Though rare, IPF has a median untreated survival of 3 years from diagnosis, making it more deadly than many cancers [2, 3]. Two anti-fibrotic therapies, pirfenidone and nintedanib, have been shown to effectively slow IPF progression, but neither stop or reverse fibrogenesis [3]. Thus, there is an urgent unmet clinical need to develop more effective treatments for IPF and identify biomarkers. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interestAuthor Disclosures: AJB has, via his institution, received consultancy fees or industry-academic funding from Ammax Bio., Devpro Bio. and Ionis Pharma. TMM has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speakers fees from Apellis, Astra Zeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Galapagos, Galecto, Genentech, GlaxoSmithKline R&D, Indalo, IQVIA, Novartis, Pliant, ProMetic, Respivant, Roche, Samumed, Theravance, UCB and Veracyte. PLM received, unrelated to the submitted work, speaker and advisory board fees from Boehringer Ingelheim and Hoffmann-La Roche, consultancy fees from Hoffman-La Roche, Boehringer Ingelheim, Trevi, Redex and AstraZeneca and industry/academic funding from AstraZeneca, via his institution. JO received consultancy fees from Boehringer Ingelheim, Lupin, Ammax Bio, roche and Veracyte. KJ and MH are or were employees of Ammax Bio. A provisonal US patent has been filed based on this work. The authors declare no further conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Oldham et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: